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Abstract
Description—The Centers for Disease Control and Prevention (CDC) and a group of 
governmental and private sector partners developed these evidence-based recommendations to 
increase the proportion of hepatitis C virus (HCV)–infected persons who know their status and are 
linked to appropriate care and treatment. The recommendations also address brief alcohol 
screening, as alcohol accelerates progression of liver disease among HCV-infected individuals. 
These recommendations augment CDC’s 1998 and 1999 recommendations based on risk and 
medical indications and are not meant to replace those recommendations.
Methods—These recommendations are based on systematic reviews of evidence published from 
1995 through February 2012 in MEDLINE, EMBASE, CINAHL, the Cochrane Central Register 
of Controlled Trials, Sociological Abstracts, and Data-base of Abstracts of Reviews of Effects. 
Selected studies included cross-sectional and cohort studies that addressed either prevalence of 
hepatitis C in the United States or clinical outcomes (for example, hepatocellular carcinoma and 
serious adverse events) among treated patients and systematic reviews of trials that assessed 
effectiveness of brief screening interventions for alcohol consumption. The Grading of 
Recommendations Assessment, Development, and Evaluation framework was used to assess 
quality of the evidence.
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Recommendation 1—Adults born during 1945–1965 should receive 1-time testing for HCV 
without prior ascertainment of HCV risk. (Grade: strong recommendation; moderate-quality 
evidence).
Recommendation 2—All persons with identified HCV infection should receive a brief alcohol 
screening and intervention as clinically indicated, followed by referral to appropriate care and 
treatment services for HCV infection and related conditions (Grade: strong recommendation; 
moderate-quality evidence).
The Centers for Disease Control and Prevention (CDC) estimates that 3.4 to 4.9 million 
persons have ever been infected with hepatitis C virus (HCV) in the United States (1). All of 
these persons develop HCV antibodies (anti-HCV), and approximately 75% develop a 
chronic infection. This results in an estimated 2.7 to 3.9 million persons living with HCV 
infection in the United States (1). Incidence of HCV increased markedly during the 1970s 
and 1980s, reaching an average of 230 000 new infections each year throughout the 1980s 
(2). Incidence declined rapidly in the 1990s because of effective screening of blood donors 
starting in 1992 and reduced numbers of new infections among persons who inject drugs. 
Incidence declined until 2006 and has since remained stable, with an estimated 17 000 new 
infections in 2010 (2). Those who were infected in the remote past have been living with 
HCV infection for 20 to 40 years and are at increased risk for HCV-related morbidity and 
mortality.
Hepatitis C virus infection is the leading indication for liver transplantation (3–6) and 
accounts for more than 50% of incident hepatocellular carcinoma (HCC), (7) the fastest-
growing cause of cancer-related death in the United States (8). Annual HCV-associated 
mortality in the United States increased over 50% from 1999 to 2007. Data from death 
certificates show that HCV-associated deaths are now more frequent than deaths caused by 
HIV (9). Modeling studies forecast substantial increases in morbidity and mortality among 
HCV-infected persons as they enter into their third, fourth, and fifth decades of living with 
infection (10, 11). The CDC estimates that without diagnosis and treatment 1.76 million 
persons with HCV infection will develop cirrhosis during their lifetimes, over 400 000 will 
develop HCC, and over 1 million will die from HCV-associated disease (10).
In 1998, the CDC issued recommendations for identifying HCV-infected persons (12). 
Testing for HCV was recommended for persons most likely to be infected, including those 
who had ever injected drugs, received clotting factor concentrates produced before 1987, 
ever received long-term hemodialysis, had laboratory evidence of liver disease (persistently 
elevated alanine aminotransferase levels), or received transfusions of blood or blood 
components or organ transplants before July 1992. Screening also was recommended for 
persons who had a recognized blood exposure (health care, emergency medical, and public 
safety workers after sticks from needles or sharps or mucosal exposure, and children born to 
HCV-infected mothers). In 1999, HCV testing was recommended for persons infected with 
HIV (13).
The success of risk-based testing strategies has been limited. Depending on the level of risk 
in the population and site-specific testing practices, an estimated 45% to 85% of U.S. adults 
are chronically infected with HCV yet unaware of their condition (14–17). Testing for HCV 
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sero-markers is suboptimal even among high-risk populations for whom routine testing is 
recommended (18, 19). A sizeable percentage of these persons remain unaware of their 
infection status (20).
Hepatitis C virus infection is typically asymptomatic until significant liver disease occurs, so 
a primary care clinician would have few reasons to order diagnostic tests on the basis of 
patient presentation. If all persons with a single elevated alanine aminotransferase level were 
tested for HCV, approximately 50% of chronic cases would remain unidentified (21) and 
20% to 30% of infected persons with persistently normal alanine aminotransferase levels 
develop serious liver disease (22). In addition, many health care providers lack knowledge 
about the prevalence, natural history, diagnostic tests, testing algorithms, and management of 
HCV infection (18, 19, 23), and accuracy of patient recall of risk behaviors, including drug 
use, decreases over time (24).
Because of the limited effectiveness of the current HCV testing recommendations alone in 
identifying undiagnosed infections, the CDC considered a birth year–based HCV testing 
strategy to increase the proportion of infected persons who know their HCV infection status: 
1-time HCV testing of persons born during 1945–1965. These persons account for 76.5% of 
all prevalence of those with HCV antibodies (25). Because alcohol accelerates progression 
of liver disease in HCV-infected persons (26), the CDC also addressed brief alcohol 
screening for those with HCV infection (27).
Target Population and Recommendation Focus
The target population was adults born or living in the United States. Efforts were focused on 
identifying testing strategies that would increase the proportion of HCV-infected persons 
who know their status. In particular, the CDC examined whether a testing strategy based on 
year of birth would identify persons living with HCV infection who have not been identified 
by risk-based testing. The CDC also considered 1) associations between achieving a 
sustained virologic response (SVR) with treatment and clinical outcomes and 2) potential 
effectiveness and benefits of offering brief alcohol interventions to HCV-infected persons.
Recommendation Development Process
A 35-member workgroup comprising persons within the CDC’s Division of Viral Hepatitis; 
members of other federal agencies; representatives from local and state health departments 
and from advocacy, community, and professional groups; clinicians; and methodologists 
guided the development of the recommendations. Table 1 shows the questions that were 
asked.
Two independent reviewers searched multiple data-bases to identify English-language 
studies pertinent to the questions. For prevalence data, we selected cross-sectional and 
cohort studies with data relevant to the United States that had been identified through 
searches of the following databases between 1995 and May 2011: MEDLINE, EMBASE, 
CINAHL, the Cochrane Central Register of Controlled Trials, Sociological Abstracts, and 
the Database of Abstracts of Reviews of Effects. We searched the same databases through 
February 2012 to identify studies that examined the association of HCC with HCV treatment 
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among persons who achieved an SVR compared with those who did not. To identify 
observational studies and controlled trials with data related to mortality, serious adverse 
events, and quality of life (QOL) among treated HCV-infected persons, we conducted a 
series of MEDLINE searches from database inception through July 2011. For evidence 
related to effective alcohol screening and counseling interventions, we selected systematic 
reviews or meta-analyses of trials that were identified in MEDLINE searches through July 
2011.
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
framework was used to develop these recommendations (28). Two investigators with 
experience using this framework independently produced evidence tables and profiles for 
each question. The criteria considered when determining the quality of the evidence were 
risk of bias, imprecision, indirectness (for example, addressing a different population than 
the one under consideration), inconsistency of results, publication bias, dose–response 
effect, magnitude of the effect, and plausible confounders. The final quality of evidence for 
the outcomes was categorized into 1 of 4 levels: very low, low, moderate, and high.
To determine the strength of the recommendations, the 9 workgroup members from the 
Division of Viral Hepatitis and the external workgroup assessed the quality of evidence, 
benefits and harms, values and preferences (of persons being targeted for testing), and 
resource implications before arriving at a consensus on the recommendations. These 
workgroup members have expertise in hepatitis C prevention, epidemiology, education and 
training, and research and evaluation, as well as in the GRADE framework. 
Recommendations can be categorized into strongly for or against the recommendation or 
conditionally for or against the recommendation.
Comments and Modification
The draft recommendations went through a peer-review and public-comment process. For 
peer review, 3 experts in the field of viral hepatitis, who had not been involved with the 
recommendation development process, commented on the draft recommendation. The draft 
recommendations were externally posted on the Federal Register Management System 
(www.regulations.gov) for public comment from 22 May to 8 June 2012. Modifications 
were made to the document on the basis of the comments received. Most comments 
requested additional information on the mode of transmission and methodological frame-
work used to grade the evidence.
Guidelines and Rationale
Recommendation 1: The CDC recommends that adults born during 1945–1965 should 
receive 1-time testing for HCV without prior ascertainment of HCV risk. (Grade: strong 
recommendation; moderate-quality evidence).
Of 31 studies that addressed the prevalence of HCV infection in the United States, 3 
involved nationally representative samples and provided evidence directly related to the 
populations of comparison: persons born during 1945–1965 living in the United States and 
the general population (1, 29, 30). These studies, as well as a recent CDC analysis of 1999 to 
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2008 NHANES (National Health and Nutrition Examination Survey) data, found that the 
proportion of persons born during 1945–1965 with HCV antibody was higher than that of 
the general population. The NHANES analysis specifically found that that the anti-HCV 
prevalence in the 1945–1965 birth cohort was 3.25%, which was substantially higher than 
that among adults aged 20 years or older who were born outside of the birth cohort (0.80%) 
(26).
Several studies examined treatment effectiveness and the relationship between achieving an 
SVR with treatment and clinical outcomes. Of note, among persons with chronic HCV 
infection, spontaneous viral clearance is highly unlikely and SVR can currently be achieved 
only by an interferon-based treatment regimen. Newer direct-acting antiviral agents increase 
the chance of SVR from an average of 41.3% for pegylated interferon and ribavirin therapy 
to nearly 70% with triple therapy (pooled risk difference, 28% [95% CI, 24% to 32%] [data 
not shown]) (30–35).
One observational study (36) providing the highest-quality evidence available relevant to 
HCV infection–related mortality among persons born during 1945–1965 found that 
achieving SVR with treatment was associated with lower risk for all-cause mortality (pooled 
unadjusted relative risk, 0.46 [CI, 0.41 to 0.51]). The study compared persons who 
responded to therapy with those who did not. It did not address a screened population or an 
untreated population. Differences in stage of liver disease between the groups had the 
potential to bias findings. However, adjusted analysis for baseline prognostic factors, 
including the presence of cirrhosis, showed a significant association between lower risk for 
mortality and SVR in patients with genotype 1 (relative risk, 0.70 [CI, 0.59 to 0.83]); lower 
risk for mortality associated with SVR also was observed among patients with genotypes 2 
and 3.
We found 30 observational studies that examined the relationship between achieving SVR 
with treatment and developing HCC. Our meta-analysis of these data found that achieving a 
treatment-related SVR was associated with a reduction in the risk for HCC among persons at 
all stages of liver disease (adjusted hazard ratio, 0.24 [CI, 0.18 to 0.31]), as well as among 
those with advanced liver disease (adjusted hazard ratio, 0.23 [CI, 0.16 to 0.35]) (36). We 
rated the certainty of these findings as moderate-quality evidence because of the large 
magnitude of effect.
Studies report that many adverse events associated with HCV treatment can lead to 
treatment discontinuation or other illnesses. Typical adverse events include infections, 
anemia, rash, pruritus, disabling fatigue, fever, nausea, diarrhea, muscle aches, and mood 
disorders that can rarely lead to suicides. More than 98% of patients undergoing treatment 
have at least 1 adverse event; however, almost all adverse events resolve when therapy is 
discontinued (35). Adding new direct-acting antiviral agents increases the risk for adverse 
events which can lead to discontinuation of treatment (relative risk, 1.34 [CI, 0.95 to 1.87] 
[data not shown]) (30–35).
One previously published systematic review examined the effect of HCV testing and 
treatment on patients’ QOL (37). Based on the Short Form-36 vitality subscore, patients 
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receiving testing and treatment had a mean QOL score that was 6.6 points higher than that of 
patients in the control group, suggesting that those who received testing and treatment had a 
higher QOL (Table 2).
A 1-time HCV test of persons born during 1945–1965 was found to be cost-effective at $35 
700 per quality-adjusted life-year gained, similar to screening for colorectal cancer, breast 
cancer, and cervical cancer (38). Average testing costs (including antibody testing, nucleic 
acid testing for persons who are antibody-positive, and posttest counseling) were estimated 
to be $54 per person, and treatment costs averaged $60 292 for genotype 1 and $12 080 for 
genotypes 2 and 3 (38).
Recommendation 2: The CDC recommends that all persons identified with HCV infection 
should receive a brief alcohol screening and intervention as clinically indicated, followed by 
referral to appropriate care and treatment services for HCV infection and related conditions 
(Grade: strong recommendation; moderate-quality evidence).
A meta-analysis of 22 randomized, controlled trials published in 2010 examined the effects 
of a brief alcohol intervention versus no intervention on reduction of alcohol use (39). 
Patients who had a brief intervention to reduce alcohol consumption had a mean reduction of 
alcohol consumed per week of 38.42 g (CI, 30.91 to 65.44 g) compared with those in the 
control group. We rated this evidence moderate quality due to indirectness because the 
studies did not specifically examine patients with HCV infection (Table 3).
Discussion
The CDC now recommends 1-time HCV testing for all persons born during 1945–1965 (27). 
These recommendations augment the CDC’s 1998 and 1999 recommendations based on risk 
and medical indications and are not meant to replace them. We judged that the benefits of 
testing and treating persons with HCV infection are greater than the harms. Although certain 
harms (that is, worry or anxiety while waiting for test results, insurability, liver biopsy 
complications, and severe adverse events during treatment) can be detrimental to patients, 
the benefits associated with diagnosis and effective treatment include SVR, which is 
associated with significant reductions in HCC and all-cause mortality.
The CDC also recommends that all infected persons receive alcohol screening and 
counseling as indicated. Brief alcohol screenings are effective in reducing alcohol use and 
maintaining that reduction for 1 year or more. Because alcohol is known to accelerate 
progression of HCV-associated liver disease (27), screening to evaluate the level of alcohol 
consumption followed by counseling to reduce or cease alcohol use can avoid this 
acceleration. Screening tools shown to be effective in eliciting history of alcohol use from 
patients include the Alcohol Use Disorders Identification Test and are available from the 
National Institute on Alcohol Abuse and Alcoholism (http://pubs.niaaa.nih.gov/publications/
Practitioner/CliniciansGuide2005/clinicians_guide.htm). The World Health Organization has 
published intervention tools to help patients reduce alcohol use (www.who.int/
substance_abuse/activities/sbi/en/index.html). Although the screening and intervention may 
be uncomfortable or cause anxiety, the benefits of alcohol reduction for persons with HCV 
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infection out-weigh those harms. Finally, the CDC recommends that all infected persons 
receive medical care (for example, hepatitis A and B virus vaccinations as needed and 
medical monitoring of disease progression), but detailed care and treatment 
recommendations are beyond the scope of these guidelines. The patient and provider should 
make treatment decisions considering such factors as disease stage, genotype, comorbid 
conditions, and adverse events of therapy.
The U.S. Preventive Services Task Force (USPSTF) and the CDC both issue preventive 
recommendations using evidence-based methods that include evaluating available data on a 
topic and drawing conclusions on the basis of the strength of the evidence. However, several 
differences exist between the organizations, including their affiliation, target audience, and 
scope. Congress created the USPSTF in 1984 as an independent panel of clinical experts to 
evaluate and make recommendations for preventive services to be delivered in the context of 
primary care. The USPSTF is not a government agency—it makes recommendations that are 
independent of the Department of Health and Human Services. The CDC is an operating 
division of the Department of Health and Human Services and clears all preventive 
recommendations with other Department of Health and Human Services agencies as 
appropriate. The USPSTF focuses on the primary care setting and provider–patient 
interactions and considers the harms and benefits (generally, reduced morbidity and 
mortality) to the patient directly resulting from a given intervention. The CDC has a broader 
public health focus that includes diverse settings outside of primary care and considers not 
only the benefits and harms of an intervention but also the potential harms of an absence of 
public health action and of future transmission of disease.
The USPSTF’s 2004 HCV screening recommendations and the CDC’s birth cohort 
recommendation are not directly comparable; updated USPSTF recommendations are 
expected within a year. In 2004, the USPSTF found insufficient evidence to recommend for 
or against HCV screening among high-risk persons (for example, persons who have ever 
injected drugs) and against routine testing for all asymptomatic adults (40). The CDC’s 
recommendation for 1-time HCV testing is only for persons born during 1945–1965, not for 
all adults. The CDC’s recommendation is, to a large degree, built on an intermediate 
measure (SVR) and its strong association with reductions in HCC and all-cause mortality.
The USPSTF prefers data from randomized, controlled trials that begin with randomization 
into screened and nonscreened groups and follow participants through to morbidity and 
mortality, but these data are not available. Although these types of studies provide the most 
conclusive evidence about the benefits and harms of a screening intervention, they also are 
resource-intensive and require long periods of follow-up. The CDC based its HCV testing 
recommendations on the prevalence in the target population, the many persons who are 
unaware of their infection status, potential benefits of care and treatment, and projections of 
increasing morbidity and mortality in the absence of an intervention.
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Table 1
Questions to Guide the Development of Recommendations
What is the effect of a testing strategy based on birth year vs. the standard of care (i.e., risk-based testing) for identification of HCV infection?
Should HCV testing (vs. no testing) be conducted among adults at average risk for infection who were born during 1945–1965?
Among persons tested for and identified with HCV infection, is treatment-related SVR (vs. treatment failure) associated with reduced liver-
related morbidity and all-cause mortality?
Should HCV testing followed by brief alcohol intervention (vs. no intervention) be carried out to reduce or stop drinking among HCV-infected 
persons?
HCV = hepatitis C virus; SVR = sustained virologic response.
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